Histogenics Corp. (HSGX) Receives Average Rating of “Buy” from Analysts
Shares of Histogenics Corp. (NASDAQ:HSGX) have been given a consensus recommendation of “Buy” by the six analysts that are covering the firm. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $7.56.
Several research analysts recently issued reports on the company. BTIG Research raised Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 target price for the company in a research report on Thursday, August 11th. Zacks Investment Research raised Histogenics Corp. from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research report on Friday, August 26th. Needham & Company LLC raised their target price on Histogenics Corp. from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, September 19th. Finally, William Blair lowered Histogenics Corp. from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 7th.
Histogenics Corp. (NASDAQ:HSGX) traded down 3.92% on Wednesday, reaching $2.94. The company’s stock had a trading volume of 7,570 shares. Histogenics Corp. has a 52-week low of $1.39 and a 52-week high of $4.97. The firm’s 50-day moving average price is $3.20 and its 200-day moving average price is $2.36. The stock’s market cap is $39.02 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/histogenics-corp-hsgx-receives-average-rating-of-buy-from-analysts.html
Histogenics Corp. (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.01. During the same quarter in the prior year, the business earned ($0.58) earnings per share. On average, equities analysts expect that Histogenics Corp. will post ($2.11) earnings per share for the current year.
In other Histogenics Corp. news, major shareholder Split Rock Partners Ii, Lp acquired 276,801 shares of the stock in a transaction dated Thursday, September 29th. The stock was purchased at an average cost of $2.25 per share, with a total value of $622,802.25. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 16.80% of the stock is owned by insiders.
A hedge fund recently raised its stake in Histogenics Corp. stock. Sabby Management LLC boosted its stake in shares of Histogenics Corp. (NASDAQ:HSGX) by 28.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 150,630 shares of the company’s stock after buying an additional 32,965 shares during the period. Sabby Management LLC owned 1.14% of Histogenics Corp. worth $345,000 as of its most recent filing with the SEC. Institutional investors own 32.30% of the company’s stock.
About Histogenics Corp.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.